A new study suggests that drugs like Ozempic and Mounjaro may reduce dementia risk. Researchers at the University of Galway ...

Weight loss jabs may offer a protective effect against dementia and stroke, according to a new study.People with type 2 diabetes and obesity who are taking the drugs are also less likely to die ...

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

Case Western Reserve researchers found semaglutide users had significantly lower Alzheimer's-related dementia risk compared ...

Diabetics are more likely to develop Alzheimer’s than the general public. Could a popular diabetes and weight-loss drug also stave off dementia?

New research suggests that semaglutide, the active ingredient in GLP-1 drugs like Ozempic and Wegovy, might protect against dementia. More than 6 million Americans are diagnosed with dementia each ...

Semaglutide, the active ingredient in popular weight loss drugs Ozempic and Wegovy, might also double as a brain booster. Research out today describes a link between semaglutide use and a reduced ...

WEIGHT loss jabs could boost men’s sex lives, a study suggests. Research found injections like Wegovy and Mounjaro can raise ...

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

Semaglutide is a glucagon-like peptide-1 (GLP-1) drug, and is the active agent in Ozempic and its weight-loss cousin, Wegovy. These medications mimic the GLP-1 hormone, which helps control insulin ...

Researchers in the U.S. and U.K. are testing Type 2 diabetes drug Ozempic and weight loss therapy Wegovy for their potential in diminishing dementia and addiction, CNBC reported Sept. 7.

Researchers analyzed 130,000 U.S. diabetes patients, including about 20,000 taking semaglutide, known by the brand name Ozempic for diabetes, or Wegovy for weight loss.